Eiken Chemical : Business Results for the First Nine Months of fiscal year ending March 31, 2023

Business Results for the First Nine Months of fiscal year ending March 31, 2023

January 30, 2023

EIKEN CHEMICAL CO., LTD

（Code：4549）

■ Consolidated financial highlights

（Million of yen）

First nine Months of fiscal year ending March 31, 2023 - Consolidated -

Net sales

（Overseas sales）

Operating profit

Ordinary profit

Profit attributable to owners of parent

Results		Ratio	YoY change
33,860		100.0%	2,029	106.4%
6,587		19.5%	△ 73	98.9%
6,999		20.7%	355		105.4%
7,107		21.0%	366		105.4%
5,361		15.8%	325		106.5%

➢ Net sales and operating income increase in revenue and profit. ✓ Demand for COVID-19 detection reagents has increased

✓ Overseas sales decrease because of stock adjustment in some area. ✓ Profit increase by change the product mix.

2

■ Related to COVID-19(SARS-CoV-2) Detection Kit

• Trend in orders for the COVID-19 detection kits－

25,000																											The 7th	7,000,000
						Orders for the detection kits															wave
						COVID-19 positives																					6,000,000
20,000																										The 8th
																														wave
15,000																														4,000,000
																														3,000,000	Loopamp SARS-CoV-2
10,000																														Detection Kit
																														2,000,000
5,000
																														1,000,000
0				2020								2021												2022						0
3	4	5	6	7	8	9 10 11 12	1	2	3	4	5	6	7	8	9	10	11	12	1	2	3	4	5	6	7	8	9	10 11	12		Loopamp Realtime Turbidimeter
																															LoopampEXIA

※ From the website of the Ministry of Health, Labour and Welfare: Covid-19 outbreaks in Japan.

3

■ Sales by Segment -Consolidated-

FIT reagents (OC)

Immunological and serological reagents

Urinalysis test strips

Microbiological reagents

Clinical chemistry reagents

Food and environment category, equipments

Molecular genetics(LAMP)

Medical devices/Others

Total

4

		（Million of yen）
First nine	First nine
months	months of	YoY ratio
of FY03/2022	FY03/2023
8,742	8,596	98.3%
7,277	7,440	102.2%
2,900	3,102	106.9%
3,077	3,045	99.0%
479	465	97.1%
1,679	1,646	98.0%
4,680	6,624	141.5%
2,993	2,939	98.2%
31,831	33,860	106.4%

			（Million of yen）
		33,860
31,831
		8,596
8,742
		7,440
7,277
		3,102
2,900	3,045
3,077	465
479	1,646
1,679
4,680	6,624
2,993	2,939
	First nine		First nine
	months		months of
	of FY03/2022		FY03/2023

■ Sales by Segment － Molecular genetics(LAMP)

➢ Sales of the COVID-19 detection reagents increase because of ｔhe 7th wave to 8th wave of the COVID-19 pandemic, driven by the omicron.

➢ License income: 1,462 million yen (previous year: 739 million yen). Temporary Lamp license incomes until the second quarter.

（Million of yen）

		First nine monthes		＊ SARS-CoV-2 is the causative virus of COVID19.
			7,445	6,624
6,390
4,391	4,680
					Loopamp SARS-CoV-2	Loopamp Realtime Turbidimeter
					Detection Kit	LoopampEXIA
					Products in a wide range of fields such as medical care,
					food and environment using our original technology LAMP.
					TB-LAMP (Tuberculosis Test) received WHO
FY03/2021	FY03/2022	FY03/2023
recommendations in 2016 and is currently being sales for

developing countries.

5